{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    14,
    17,
    37,
    41,
    47,
    52
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Diet and Exercise Counseling",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.9.3",
        "sectionTitle": "Diet and Exercise Counseling",
        "description": "Reference for subjects to adhere to diet and exercise counseling"
      },
      {
        "id": "ref_2",
        "name": "Study Flow Chart",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Study Flow Chart/Time and Event Schedule",
        "description": "Reference to the study flow chart and time/event schedule"
      },
      {
        "id": "ref_3",
        "name": "Birth Control Method",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.4",
        "sectionTitle": "Women of Childbearing Potential",
        "description": "Reference for women of child-bearing potential regarding birth control"
      },
      {
        "id": "ref_4",
        "name": "Hypoglycemia Episode",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.5.1",
        "sectionTitle": "Discontinuation Guidelines due to Protocol-Defined Hypoglycemia",
        "description": "Reference for protocol-defined hypoglycemia episodes leading to discontinuation"
      },
      {
        "id": "ref_5",
        "name": "CGM Requirements",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.9.4.3",
        "sectionTitle": "Continuous Glucose Monitoring",
        "description": "Reference for CGM requirements if a subject fails lead-in or for phone visits"
      },
      {
        "id": "ref_6",
        "name": "Table 4-1 Footnote a",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 4-1",
        "sectionTitle": "Study Drug Product Description",
        "description": "Reference to footnote regarding 10 mg and 5 mg kit packaging"
      },
      {
        "id": "ref_7",
        "name": "Table 4-1 Footnote b",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 4-1",
        "sectionTitle": "Study Drug Product Description",
        "description": "Reference to footnote regarding placebo kit packaging"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Subjects are not allowed to change their insulin administration methods (MDI or CSII) throughout the study.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "3.5 Discontinuation of Subjects from Treatment",
        "pageNumber": 38
      },
      {
        "id": "annot_2",
        "text": "Blinded dapagliflozin 10 mg kit contains 2 bottles of dapagliflozin 5 mg film-coated tablets (35 count)",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 4-1",
        "pageNumber": 42
      },
      {
        "id": "annot_3",
        "text": "Blinded dapagliflozin 5 mg kit contains 1 bottle of dapagliflozin 5 mg film-coated tablets and 1 bottle of placebo",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 4-1",
        "pageNumber": 42
      },
      {
        "id": "annot_4",
        "text": "If a lead-in subject fails lead-in prior to the Day 1 visit, the CGM will not be required to be completed",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 5.1-1",
        "pageNumber": 48
      },
      {
        "id": "annot_5",
        "text": "Tubal Ligation in this protocol is not considered surgical sterilization",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Amendment 05 Summary",
        "pageNumber": 4
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "02",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2016-05-18",
        "description": "Revised Protocol 02 incorporating Amendment 05 regarding phone visit flexibility and DKA guidance",
        "amendmentNumber": "05"
      },
      {
        "id": "ver_2",
        "versionNumber": "01",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2015-05-06",
        "description": "Revised Protocol 01 incorporating Amendment 03 regarding EMA feedback on HbA1c",
        "amendmentNumber": "03"
      },
      {
        "id": "ver_3",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2015-02-05",
        "description": "Original Protocol",
        "amendmentNumber": "N/A"
      }
    ],
    "summary": {
      "referenceCount": 7,
      "annotationCount": 5,
      "versionCount": 3
    }
  }
}